Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-32)

In this article we will discuss Durvalumab (Warnings-32)

In this article, we will discuss Durvalumab (Warnings-32). So, let’s get started.

Musculoskeletal and connective tissue disorders: Myositis/polymyositis, rhabdomyolysis, and associated
sequelae, including renal failure, arthritis, polymyalgia rheumatic.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.